| Molecule Name |
DB00176
|
| DrugBank Groups |
Approved
|
| Cluster No |
48
|
| Smiles |
FC(F)(F)C1(=CC=C(C(=NOCCN)CCCCOC)C=C1)
|
| Download |
mol2, pdbqt
|
| TPSA |
56,84
|
| Non-H Atoms |
22
|
| Non-C/H Atoms |
7
|
| Metal-Atoms |
0
|
| Electronegative Atoms |
7
|
| Stereo Centers |
0
|
| Rotatable Bonds |
10
|
| Rings Closures |
1
|
| Small Rings |
1
|
| Aromatic Rings |
1
|
| Aromatic Atoms |
6
|
| sp3-Atoms |
11
|
| Symmetric atoms |
4
|
| cLogS |
-3,757
|
| MW |
318,338
|
| cLogP |
3,15
|
| HBA |
4
|
| HBD |
1
|
| Ro5 violations |
0
|
| Druglikeness |
-11,561
|
| DrugScore |
0,392843076501233
|
| Mutagenic |
none
|
| Tumorigenic |
none
|
| Reproductive Effective |
none
|
| Irritant |
none
|
| Blood-Brain Barrier |
BBB+
|
| Human Intestinal Absorption |
HIA+
|
| Caco-2 Permeability |
Caco2-
|
| P-glycoprotein Substrate |
Substrate
|
| P-glycoprotein Inhibitor |
Inhibitor
|
| P-glycoprotein Inhibitor 2 |
Non-inhibitor
|
| Renal Organic Cation Transporter |
Non-inhibitor
|
| Aqueous solubility |
-3,0217
|
| Caco-2 Permeability 2 |
1,0407
|
| Subcellular localization |
Lysosome
|
| CYP450 2C9 Substrate |
Non-substrate
|
| CYP450 2D6 Substrate |
Substrate
|
| CYP450 3A4 Substrate |
Non-substrate
|
| CYP450 1A2 Inhibitor |
Inhibitor
|
| CYP450 2C9 Inhibitor |
Inhibitor
|
| CYP450 2D6 Inhibitor |
Inhibitor
|
| CYP450 2C19 Inhibitor |
Inhibitor
|
| CYP450 3A4 Inhibitor |
Inhibitor
|
| CYP Inhibitory Promiscuity |
Low CYP Inhibitory Promiscuity
|
| Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
| Human Ether-a-go-go-Related Gene Inhibition 2 |
Inhibitor
|
| AMES Toxicity |
Non AMES toxic
|
| Carcinogens |
Non-carcinogens
|
| Fish Toxicity |
High FHMT
|
| Fish Toxicity (pLC50, mg/L) |
1,4625
|
| Tetrahymena Pyriformis Toxicity |
High TPT
|
| Tetrahymena Pyriformis Toxicity (pIGC50, ug/L) |
0,5268
|
| Honey Bee Toxicity |
Low HBT
|
| Biodegradation |
Not ready biodegradable
|
| Acute Oral Toxicity |
III
|
| Rat Acute Toxicity (LD50, mol/kg) |
2,6997
|
| Carcinogenicity (Three-class) |
Non-required
|
